Corifollitropin alfa

Drug Profile

Corifollitropin alfa

Alternative Names: Elonva; Follitropin-stimulating hormone long-acting; FSH long-acting; FSH-CTP; Long-acting follicle-stimulating hormone; MK-8962; ORG-36286; SCH-900962

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Organon
  • Developer Merck & Co
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility
  • Phase III Hypogonadism

Most Recent Events

  • 01 Feb 2017 Phase-III clinical trials in Hypogonadism (In adolescents) in Russia (SC) (NCT03019575)
  • 11 Jan 2017 Merck Sharp & Dohme plans a phase III trial for Hypogonadotropic hypogonadism (Combination therapy, In adolescents) in Russia (SC, Injection) (NCT03019575)
  • 02 Sep 2015 No recent reports on development identified - Phase-III for Female infertility in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top